FindTrial
Sign In

Clinical effects of Remimazolam combined propofol in different synergistic ratios for hysteroscopy

Clinical effects of Remimazolam combined propofol in different synergistic ratios for hysteroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098082
Enrollment
Unknown
Registered
2025-03-03
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group A:Intravenous injection: Remimazolam 0.1 mg/kg + Propofol 0.4 mg/kg
Group B:Intravenous injection: Remimazolam 0.08 mg/kg + Propofol 0.64 mg/kg
Group C:Intravenous injection: Remimazolam 0.06 mg/kg + Propofol 0.72mg/kg

Sponsors

The Third Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing hysteroscopy under general anesthesia 2. Age 20-45 years old 3. BMI18~28kg/m 4. ASA Grade ? or ?

Exclusion criteria

Exclusion criteria: 1. Anemia (Hb < 90g/L) 2. Malnutrition (albumin < 30g/L) 3. History of mental illness 4. History of taking sedative hypnotic drugs

Design outcomes

Primary

MeasureTime frame
24h quality of recovery(24h QoR);—

Secondary

MeasureTime frame
Total dosage of remimazolam and propofol;Time to awake;Postoperative recovery time;Pain of injection;PACU and postoperative nausea and vomiting within 24 hours;Hypotension;Bradycardia;Hiccup;Number of body movements;—

Countries

China

Contacts

Public ContactGao Wenlong

The Third Affiliated Hospital of Zhengzhou University.

gaowenlong3862@outlook.com+86 185 3816 7939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026